Page last updated: 2024-12-06
tinazoline
Description
Tinazoline is an α-adrenergic agonist that is used as a nasal decongestant. It is available as a nasal spray and is often used to relieve congestion associated with the common cold, sinusitis, and allergic rhinitis. Tinazoline works by constricting blood vessels in the nasal passages, which reduces swelling and congestion. It is generally well-tolerated, but some side effects may occur, such as burning or stinging in the nose, headache, and insomnia. Tinazoline is not recommended for use in children under 12 years of age or in people with high blood pressure, heart disease, or glaucoma.'
tinazoline: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 68818 |
| CHEMBL ID | 2107015 |
| CHEBI ID | 134897 |
| SCHEMBL ID | 828318 |
| MeSH ID | M0103182 |
Synonyms (21)
| Synonym |
|---|
| 62882-99-9 |
| tinazoline |
| CHEBI:134897 |
| 3-(4,5-dihydro-1h-imidazol-2-ylsulfanyl)-1h-indole |
| CHEMBL2107015 |
| tinazolina [inn-spanish] |
| 3-(2-imidazolin-2-ylthio)indole |
| 1h-indole, 3-((4,5-dihydro-1h-imidazol-2-yl)thio)-, monohydrochloride |
| tinazolinum [inn-latin] |
| tinazolinum |
| tinazolina |
| tinazoline [inn] |
| unii-88174ak70t |
| 88174ak70t , |
| SCHEMBL828318 |
| AKOS027201113 |
| STL509721 |
| Z1509151981 |
| Q27269870 |
| DTXSID90866955 |
| EN300-253143 |
Drug Classes (1)
| Class | Description |
|---|
| indoles | Any compound containing an indole skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |